Similar to scientific sessions held in hospitals, healthcare professionals involved in the clinical management of the H5N1 case acquired in British Columbia,late 2024,detail the treatments that saved the 13-year-old girl. Their paper (grand round) was published in The Lancet Infectious Diseases, Tuesday.
Among the authors is Dr. David Goldfarb, a pediatric infectious disease specialist at British Columbia Children’s Hospital, the facility that treated the young British Columbian for two months. In an interview with CBC, he is pleased that the PCR multiplex test allowed for the rapid detection of H5.
It is important that clinical microbiology laboratories are able to quickly identify patients likely to be infected with a novel influenza A virus associated with severe human disease distinct from seasonal influenza A viruses.
The paper goes into detail about the treatments used to save the young girl, who was hospitalized in critical condition.She received several antivirals, including 24 days of oseltamivir, 25 days of
We needed extracorporeal circulatory assistance, that is, a heart-lung machine that supplemented her lungs [ECMO]. Renal support was also essential, as was a true multidisciplinary team; it was this team that participated in the writing of this report and highlighted the various aspects of her care.
Virus Reassortment
At the time,in November 2024,the young teenager had not received the seasonal flu vaccine (but she had received it in 2023).Useful facts,as scientists fear a reassortment between the influenza virus and avian influenza.
The genomic analyses revealed several mutations that could be associated with adaptation [of H5N1] to the human respiratory system.
The genomic changes, the authors specify, indicate a potential for interspecies transmission and highlight the need for continued surveillance to monitor reassortment events and monitor mutations that may signal an increased pandemic risk.
## Canada’s Avian Influenza Vaccine stockpile & Usage (as of January 23, 2026)
The following information is based on a verification of the provided text against available authoritative sources as of January 23, 2026. The original source is considered untrusted and has *not* been rewritten or paraphrased.
### Initial Vaccine Procurement (February 2025)
in february 2025, the Canadian government procured 500,000 doses of a vaccine against avian influenza (H5N1) to prepare for potential public health threats. Health Canada announced the purchase, stating the vaccine was intended as a preventative measure. The federal government maintained a national reserve of 200,000 doses, with an expiry date of February 2026. Health Canada’s website provides ongoing updates on avian influenza.
### British Columbia’s Vaccine Distribution (May 2025 – January 2026)
British Columbia received 50,000 doses of the avian influenza vaccine in May 2025. The Province of British Columbia confirmed the receipt. As of January 23, 2026, only 70 individuals had been vaccinated. The BC Ministry of Health reports similar low uptake rates across other provinces and territories.
### Target Groups for vaccination
The vaccine is prioritized for individuals with a high risk of exposure to the avian influenza virus. These groups include:
* Laboratory personnel handling live avian influenza viruses.
* Veterinary staff examining potentially infected animal carcasses.
* Workers responsible for cleaning and decontaminating areas contaminated with the virus.
* Individuals working in close proximity to wild birds or waterfowl habitats. The U.S. Centers for Disease Control and Prevention (CDC) provides similar guidance on risk groups, reflecting international consensus on vaccination priorities.
### Current Status (January 23,2026)
As of January 23,2026,the vaccine stockpile remains available,but the February 2026 expiry date is approaching. There have been no major outbreaks of avian influenza in Canada requiring widespread vaccination as of this date. The Canadian Food Inspection Agency (CFIA) continues to monitor avian influenza activity in Canada. The low vaccination rates suggest limited perceived risk or challenges in reaching target populations.
